Article
Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data.
PloS one - 1 Jan 2011
Armistead Paul M, Liang Shoudan, Li Hua, Lu Sijie, Van Bergen Cornelis A M, Alatrash Gheath, St John Lisa, Hunsucker Sally A, Sarantopoulos Stefanie, Falkenburg J H Frederik, Molldrem Jeffrey J
Abstract excerpt
BACKGROUND: Minor histocompatibility antigens (mHA) mediate much of the graft vs. leukemia (GvL) effect and graft vs. host disease (GvHD) in patients who undergo allogeneic stem cell transplantation (SCT). Therapeutic decision making and treatments based upon mHAs will require the evaluation of multiple candidate mHAs and the selection of those with the potential to have the greatest impact on clinical outcomes....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.